Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

Blood

Volumn 127, Issue 18, 2016, Pages 2182-2188

  Savage, Kerry J ^a   Slack, Graham W ^a   Mottok, Anja ^a   Sehn, Laurie H ^a   Villa, Diego ^a   Kansara, Roopesh ^b   Kridel, Robert ^a   Steidl, Christian ^a   Ennishi, Daisuke ^a   Tan, King L ^a   Ben Neriah, Susana ^a   Johnson, Nathalie A ^c   Connors, Joseph M ^a   Farinha, Pedro ^a   Scott, David W ^a   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FORMALDEHYDE; METHOTREXATE; MYC PROTEIN; PARAFFIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; B LYMPHOCYTE; BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CENTRAL NERVOUS SYSTEM; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE EXPRESSION ASSAY; GENETIC ASSOCIATION; GERMINAL CENTER; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; ADOLESCENT; AGED; CELL LINEAGE; CHEMISTRY; GENE TRANSLOCATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK; TISSUE MICROARRAY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CELL LINEAGE; CENTRAL NERVOUS SYSTEM; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECURRENCE; RISK; RITUXIMAB; TISSUE ARRAY ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84969143074     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-676700     Document Type: Article

References (38)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4): 235-242.
2. Pfreundschuh M, Kuhnt E, Trümper L, et al; MabThera International Trial (MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013-1022.
3. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127.
4. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
5. Boehme V, Zeynalova S, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157.
6. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5): 1046-1052.
7. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003; 101(2):466-468.
8. Schmitz N, Zeynalova S, Nickelsen M, et al. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma [abstract]. Hematol Oncol. 2013; 31(Suppl 1):11. Abstract 047.
9. Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma [abstract]. Blood. 2014; 124(21). Abstract 394.
10. El-Galaly TC, Cheah CY, Villa D, et al. Validation of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) prognostic model for CNS relapse in a large cohort of PET/ CT staged patients [abstract]. Hematol Oncol. 2015;33:171. Abstract 131.
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
12. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100(17):9991-9996.
13. Lenz G, Wright G, Dave SS, et al; Lymphoma/ Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
14. Scott DW, Mottok A, Ennishi D, et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol. 2015;33(26): 2848-2856.
15. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14; 18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145-156.
16. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-2361.
17. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30(28):3452-3459.
18. Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28): 3460-3467.
19. Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/ BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20): 4021-4031.
20. Horn H, Ziepert M, Becher C, et al; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large Bcell lymphoma. Blood. 2013;121(12):2253-2263.
21. Ennishi D, Hoffer C, Shulha H, et al. Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma [abstract]. Blood. 2014; 124(21). Abstract 703.
22. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95(6):2084-2092.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
24. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123(8):1214-1217.
25. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
26. Copie-Bergman C, Cuillière-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126(22):2466-2474.
27. Cox MC, Di Napoli A, Scarpino S, et al. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. PLoS One. 2014; 9(4):e93903.
28. Braggio E, Van Wier S, Ojha J, et al. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res. 2015;21(17): 3986-3994.
29. Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas [published online ahead of print June 25, 2015]. Neuropathol Appl Neurobiol. doi:10.1111/ nan.12259.
30. Yamada S, Ishida Y, Matsuno A, Yamazaki K. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015;56(7): 2141-2145.
31. Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010; 116(18):4283-4290.
32. Cheah CY, Herbert KE, O'Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072-1079.
33. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-926.
34. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/ refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011; 117(22):5058-5066.
35. Dunleavy K, Lai CE, Roschewski M, et al. Phase I study of dose-adjusted Teddi-R with Ibrutinib in untreated and relapsed/refractory primary CNS lymphoma [abstract]. Blood. 2015;126(23). Abstract 472.
36. Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015; 126(14):1695-1698.
37. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251-257.
38. Vitolo U, Chiappella A, Franceschetti S, et al; Fondazione Italiana Linfomi. Lenalidomide plus RCHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730-737.